Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review.

Gabe MBN, van der Velden WJC, Smit FX, Gasbjerg LS, Rosenkilde MM.

Peptides. 2019 Dec 3:170224. doi: 10.1016/j.peptides.2019.170224. [Epub ahead of print] Review.

2.

Striatal Involvement in Neurodegenerative Langerhans Cell Histiocytosis.

de Haan S, van der Velden WJFM, Meijer FJA.

Mov Disord Clin Pract. 2019 Oct 25;6(8):719-721. doi: 10.1002/mdc3.12844. eCollection 2019 Nov. No abstract available.

PMID:
31745486
3.

Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system.

Gabe MBN, van der Velden WJC, Gadgaard S, Smit FX, Hartmann B, Bräuner-Osborne H, Rosenkilde MM.

Basic Clin Pharmacol Toxicol. 2019 Jul 12. doi: 10.1111/bcpt.13289. [Epub ahead of print]

PMID:
31299132
4.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16. No abstract available.

5.

Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects.

de Kort EA, van Dorp S, Blijlevens NMA, van der Velden WJFM.

Bone Marrow Transplant. 2020 Jan;55(1):253-255. doi: 10.1038/s41409-019-0526-0. Epub 2019 Apr 10. No abstract available.

PMID:
30971779
6.

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.

de Kort EA, de Lil HS, Bremmers MEJ, van Groningen LFJ, Blijlevens NMA, Huls G, Brüggemann RJM, van Dorp S, van der Velden WJFM.

PLoS One. 2019 Mar 21;14(3):e0213913. doi: 10.1371/journal.pone.0213913. eCollection 2019.

7.

[Ring-shaped lesions on a lung scan].

Coşkuntürk M, Aarntzen EHJG, van der Velden WJFM.

Ned Tijdschr Geneeskd. 2019 Jan 30;163. pii: D3417. Dutch.

PMID:
30719883
8.

Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, Masereeuw R, Netea MG, Levine JE, Morales G, Ferrara JL, Blijlevens NMA, van Oosterhout YVJM, Stelljes M, van der Velden WJFM.

Biol Blood Marrow Transplant. 2019 Apr;25(4):712-719. doi: 10.1016/j.bbmt.2018.10.020. Epub 2018 Nov 3.

PMID:
30399420
9.

Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study.

Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, Schalekamp S, van der Velden WJFM, Kuiper EJ, van Paassen J, van der Hoven B, van der Lee HA, Melchers WJG, de Haan AF, van der Hoeven HL, Rijnders BJA, van der Beek MT, Verweij PE.

Clin Infect Dis. 2019 Apr 24;68(9):1463-1471. doi: 10.1093/cid/ciy859.

PMID:
30307492
10.

Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.

Ortiz Zacarías NV, van Veldhoven JPD, Portner L, van Spronsen E, Ullo S, Veenhuizen M, van der Velden WJC, Zweemer AJM, Kreekel RM, Oenema K, Lenselink EB, Heitman LH, IJzerman AP.

J Med Chem. 2018 Oct 25;61(20):9146-9161. doi: 10.1021/acs.jmedchem.8b00605. Epub 2018 Oct 11.

11.

Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.

Muilwijk EW, Maertens JA, van der Velden WJFM, Ter Heine R, Colbers A, Burger DM, Andes D, Theunissen K, Blijlevens NMA, Brüggemann RJM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3095-3101. doi: 10.1093/jac/dky324.

PMID:
30137340
12.

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M.

Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7.

PMID:
30064039
13.

Activity of decitabine in pericardial myeloid sarcoma.

Evers D, Bär BMAM, Gotthardt M, van der Velden WJFM.

Int J Hematol. 2018 Aug;108(2):121-122. doi: 10.1007/s12185-018-2470-y. Epub 2018 May 19. No abstract available.

PMID:
29779081
14.

Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.

Vreugdenhil B, van der Velden WJFM, Feuth T, Kox M, Pickkers P, van de Veerdonk FL, Blijlevens NMA, Brüggemann RJM.

Br J Clin Pharmacol. 2018 Sep;84(9):1980-1988. doi: 10.1111/bcp.13627. Epub 2018 Jun 19.

15.

The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.

Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Brüggemann RJ, Biemond BJ, Bart A, von dem Borne PA, Verbon A, van der Beek MT, Demandt AMP, Oudhuis GJ, Cornelissen JJ, van der Velden WJFM, Span LFR, Kampinga GA, Bruns AH, Vonk AG, Haas PA, Doorduijn JK, Rijnders BJA.

Mycoses. 2018 Sep;61(9):656-664. doi: 10.1111/myc.12788. Epub 2018 Jul 13.

PMID:
29687483
16.

Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study.

Lestrade PP, van der Velden WJFM, Bouwman F, Stoop FJ, Blijlevens NMA, Melchers WJG, Verweij PE, Donnelly JP.

J Antimicrob Chemother. 2018 May 1;73(5):1389-1394. doi: 10.1093/jac/dkx527.

PMID:
29394399
17.

Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice.

Cany J, Roeven MWH, Hoogstad-van Evert JS, Hobo W, Maas F, Franco Fernandez R, Blijlevens NMA, van der Velden WJ, Huls G, Jansen JH, Schaap NPM, Dolstra H.

Blood. 2018 Jan 11;131(2):202-214. doi: 10.1182/blood-2017-06-790204. Epub 2017 Nov 14.

18.

Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation.

van der Velden WJFM, de Weerd-de Jong EC, de Haan AFJ, Blijlevens NMA.

Biol Blood Marrow Transplant. 2018 Feb;24(2):410-412. doi: 10.1016/j.bbmt.2017.10.020. Epub 2017 Oct 16. No abstract available.

19.

Targeting the interleukin-1 pathway in patients with hematological disorders.

de Mooij CEM, Netea MG, van der Velden WJFM, Blijlevens NMA.

Blood. 2017 Jun 15;129(24):3155-3164. doi: 10.1182/blood-2016-12-754994. Epub 2017 May 8. Review.

PMID:
28483765
20.

'Trained immunity': consequences for lymphoid malignancies.

Stevens WB, Netea MG, Kater AP, van der Velden WJ.

Haematologica. 2016 Dec;101(12):1460-1468. Epub 2016 Nov 10. Review.

21.

Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.

van den Brand M, Rijntjes J, Hebeda KM, Menting L, Bregitha CV, Stevens WB, van der Velden WJ, Tops BB, van Krieken JH, Groenen PJ.

Histopathology. 2017 Jan;70(2):174-184. doi: 10.1111/his.13015. Epub 2016 Sep 9.

PMID:
27297871
22.

Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: coincidence or correlated?

Olde Bekkink M, Ahmed-Ousenkova YM, Netea MG, van der Velden WJ, Berden JH.

Lupus. 2016 Jun;25(7):766-71. doi: 10.1177/0961203316636466. Epub 2016 Mar 4.

PMID:
26946293
23.

Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.

Cruijsen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, Falkenburg JHF, Kester M, Schaap NPM, Jansen J, Blijlevens NNM, Dolstra H, Huls G.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1000-1008. doi: 10.1016/j.bbmt.2016.02.003. Epub 2016 Feb 6.

24.

Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation.

van den Brand M, van der Velden WJ, Diets IJ, Ector GI, de Haan AF, Stevens WB, Hebeda KM, Groenen PJ, van Krieken HJ.

Leuk Lymphoma. 2016 Jul;57(7):1649-56. doi: 10.3109/10428194.2015.1106535. Epub 2015 Dec 23.

PMID:
26694256
25.

Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.

van Groningen LF, Liefferink AM, de Haan AF, Schaap NP, Donnelly JP, Blijlevens NM, van der Velden WJ.

Biol Blood Marrow Transplant. 2016 Jan;22(1):179-82. doi: 10.1016/j.bbmt.2015.08.039. Epub 2015 Sep 18.

26.

[Severe inflammation during recovery from neutropenia: the immune reconstitution inflammatory syndrome following chemotherapy].

van Lier DP, Janssen NA, Snoeren MM, Verweij PE, Blijlevens NM, van der Velden WJ.

Ned Tijdschr Geneeskd. 2015;159:A8968. Review. Dutch.

PMID:
26246060
27.

Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis.

van de Veerdonk FL, Koenen HJ, van der Velden WJ, van der Meer JW, Netea MG.

Immunol Lett. 2015 Sep;167(1):54-6. doi: 10.1016/j.imlet.2015.05.008. Epub 2015 May 18. No abstract available.

PMID:
25999307
28.

A patient with flank pain and haematuria after allogeneic stem cell transplantation.

Berrevoets MA, Verweij PE, van der Velden WJ.

Neth J Med. 2015 May;73(4):187-9. No abstract available.

29.

A "body armor" of leukemia cutis.

Janssen NA, Hebeda KM, Stevens WB, van der Velden WJ.

Am J Hematol. 2015 Aug;90(8):751. doi: 10.1002/ajh.23948. Epub 2015 Feb 25. No abstract available.

30.

Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders.

van der Velden WJ, Nissen L, van Rijn M, Rijntjes J, de Haan A, Venkatraman L, Catherwood M, Liu H, El-Daly H, van de Laar L, Craenmehr MH, van Krieken JH, Stevens WB, Groenen PJ.

Haematologica. 2015 Apr;100(4):e152-4. doi: 10.3324/haematol.2014.116780. Epub 2014 Dec 19. No abstract available.

31.

A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.

Brüggemann RJ, Van Der Velden WJ, Knibbe CA, Colbers A, Hol S, Burger DM, Donnelly JP, Blijlevens NM.

J Antimicrob Chemother. 2015 Apr;70(4):1166-74. doi: 10.1093/jac/dku477. Epub 2014 Dec 3.

PMID:
25473029
32.

Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis.

van der Velden WJ, Herbers AH, Netea MG, Blijlevens NM.

Br J Haematol. 2014 Nov;167(4):441-52. doi: 10.1111/bjh.13113. Epub 2014 Sep 6. Review.

PMID:
25196917
33.

Atypical presentation of 'acalculous cholecystitis' with marked isolated hyperbilirubinaemia in patients treated for haematological malignancies.

Berrevoets MA, Hermans JJ, Wanten GJ, van der Velden WJ.

Eur J Haematol. 2015 Feb;94(2):182-5. doi: 10.1111/ejh.12357. Epub 2014 May 21.

PMID:
24766347
34.

Host impairments in patients with neoplastic diseases.

Donnelly JP, Blijlevens NM, van der Velden WJ.

Cancer Treat Res. 2014;161:1-41. doi: 10.1007/978-3-319-04220-6_1. Review.

PMID:
24706220
35.

Trends in the outcomes of Dutch haematological patients receiving intensive care support.

van Vliet M, van der Burgt MP, van der Velden WJ, van der Hoeven JG, de Haan AF, Donnelly JP, Pickkers P, Blijlevens NM.

Neth J Med. 2014 Feb;72(2):107-12.

36.

Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.

Herbers AH, de Haan AF, van der Velden WJ, Donnelly JP, Blijlevens NM.

Transpl Infect Dis. 2014 Apr;16(2):279-85. doi: 10.1111/tid.12195. Epub 2014 Mar 13.

PMID:
24621081
37.

Targeting the IL17 pathway for the prevention of graft-versus-host disease.

van der Waart AB, van der Velden WJ, Blijlevens NM, Dolstra H.

Biol Blood Marrow Transplant. 2014 Jun;20(6):752-9. doi: 10.1016/j.bbmt.2014.02.007. Epub 2014 Feb 22. Review.

38.

Incidence of and risk factors for persistent gram-positive bacteraemia and catheter-related thrombosis in haematopoietic stem cell transplantation.

Richters A, van Vliet M, Peer PG, Verweij PE, Laros-van Gorkom BA, Blijlevens NM, Donnelly JP, van der Velden WJ.

Bone Marrow Transplant. 2014 Feb;49(2):264-9. doi: 10.1038/bmt.2013.172. Epub 2013 Nov 4.

PMID:
24185587
39.

Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.

Herbers AH, van der Velden WJ, de Haan AF, Donnelly JP, Blijlevens NM.

Bone Marrow Transplant. 2014 Jan;49(1):8-10. doi: 10.1038/bmt.2013.118. Epub 2013 Aug 19.

PMID:
23955637
40.

Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab.

van der Velden WJ, Mori T, Stevens WB, de Haan AF, Stelma FF, Blijlevens NM, Donnelly JP.

Bone Marrow Transplant. 2013 Nov;48(11):1465-71. doi: 10.1038/bmt.2013.84. Epub 2013 Jun 10.

PMID:
23749107
41.

A "complicated" fracture: a Philadelphia chromosome-positive myeloid sarcoma of the bone.

van Groningen LF, Preijers FW, Jansen JH, Hebeda KM, van der Velden WJ.

Ann Hematol. 2013 Sep;92(9):1287-8. doi: 10.1007/s00277-013-1691-7. Epub 2013 Feb 13. No abstract available.

PMID:
23404583
42.

Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT.

van der Velden WJ, Herbers AH, Brüggemann RJ, Feuth T, Peter Donnelly J, Blijlevens NM.

Bone Marrow Transplant. 2013 Jul;48(7):977-81. doi: 10.1038/bmt.2012.278. Epub 2013 Jan 21.

PMID:
23334276
43.

Decreased levels of circulating IL17-producing CD161+CCR6+ T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation.

van der Waart AB, van der Velden WJ, van Halteren AG, Leenders MJ, Feuth T, Blijlevens NM, van der Voort R, Dolstra H.

PLoS One. 2012;7(12):e50896. doi: 10.1371/journal.pone.0050896. Epub 2012 Dec 4.

44.

Abdominal compartment syndrome in neutropenic enterocolitis.

van Vliet M, van der Hoeven HJ, van der Velden WJ.

Br J Haematol. 2013 Feb;160(3):273. doi: 10.1111/bjh.12140. Epub 2012 Dec 4. No abstract available.

PMID:
23206290
45.

Role of the mycobiome in human acute graft-versus-host disease.

van der Velden WJ, Netea MG, de Haan AF, Huls GA, Donnelly JP, Blijlevens NM.

Biol Blood Marrow Transplant. 2013 Feb;19(2):329-32. doi: 10.1016/j.bbmt.2012.11.008. Epub 2012 Nov 15.

46.

Systematic review of agents for the management of gastrointestinal mucositis in cancer patients.

Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S, Bowen JM; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2013 Jan;21(1):313-26. doi: 10.1007/s00520-012-1644-z. Epub 2012 Nov 10. Review.

PMID:
23142924
47.

Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

Hobo W, Broen K, van der Velden WJ, Greupink-Draaisma A, Adisty N, Wouters Y, Kester M, Fredrix H, Jansen JH, van der Reijden B, Falkenburg JH, de Witte T, Preijers F, Schattenberg T, Feuth T, Blijlevens NM, Schaap N, Dolstra H.

Biol Blood Marrow Transplant. 2013 Feb;19(2):274-82. doi: 10.1016/j.bbmt.2012.09.008. Epub 2012 Sep 27.

48.

Lymphocyte subsets, granulocyte-colony-stimulating factor responsiveness and post-stem cell transplantation infections: mucositis is the underestimated confounder?

van der Velden WJ, Donnelly JP, Blijlevens NM.

Cytotherapy. 2012 Mar;14(3):381-3. doi: 10.3109/14653249.2011.650162. Epub 2012 Jan 16. No abstract available.

PMID:
22242829
49.

A Sézary cryptogram. Disseminated cryptococcal infection.

Desar IM, Stevens WB, Verweij PE, van der Velden WJ.

Neth J Med. 2011 Jul-Aug;69(7):346, 349. No abstract available.

50.

Genetic variants and the risk for invasive mould disease in immunocompromised hematology patients.

van der Velden WJ, Blijlevens NM, Donnelly JP.

Curr Opin Infect Dis. 2011 Dec;24(6):554-63. doi: 10.1097/QCO.0b013e32834ab1f4. Review.

PMID:
21926619

Supplemental Content

Loading ...
Support Center